Red Wine Chemical Enhances Mesothelioma Chemotherapy

A new experimental treatment combining a chemical found in red wine and a popular chemotherapy drug showed a powerful synergistic effect in targeting pleural mesothelioma cells. Researchers at Soon Chun Hyang University Hospital Cheonan in South Korea combined the platinum-based chemotherapy drug cisplatin with resveratrol, a natural antioxidant found in wine and red grapes. The result successfully induced apoptosis, or the process of natural cell death, in malignant mesothelioma cells. Cisplatin has long been one of the most popular drugs to treat mesothelioma and a variety of other cancers. But like many chemotherapy drugs, cisplatin’s efficacy remains limited. Resistance can develop following prolonged cycles or can be present innately in patients. The resveratrol made mesothelioma cells much more vulnerable to cisplatin, an effect Soon Chun Hyang researchers hope will translate into future treatment options. Furthermore, the data showed the increased resistance of the cells is related to the activation of self-defensive autophagy, or the destructive mechanism of the cell that disassembles unnecessary or dysfunctional components. “The molecular basis of the synergistic anti-cancer activities of [cisplatin] and [resveratrol] is not yet understood in detail,” lead investigator Yoon-Jin Lee wrote in the study. “However, emerging studies have revealed that [resveratrol] acts as an excellent candidate for potentiation of platinum treatment in vitro ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: chemotherapy for mesothelioma cisplatin for mesothelioma mesothelioma treatment with red wine red wine for cancer resveratrol and cisplatin for cancer resveratrol in red wine Soon Chun Hyang University Hospital Cheonan Source Type: news

Related Links:

Sarah Cannon Research Institute in Nashville, Tennessee, and MD Anderson Cancer Center in Houston have opened a much-anticipated clinical trial involving a novel T-cell therapy for patients with mesothelioma. The two institutions are establishing dosage levels and measuring efficacy of TC-210, a type of immunotherapy that targets mesothelin, a cell surface protein highly expressed in several cancers. The study also is open to patients with certain types of bile duct, ovarian and non-small cell lung cancer. Participation is based upon individual levels of mesothelin expression. Researchers at the two centers are hoping to ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
In this study we tested the clinoptilolite, chabazite, and natrolite ability to be loaded by antitumor ribonuclease binase and the cytotoxicity of the obtained complexes. We found the optimal conditions for binase loading into zeolites and established the dynamic of its release. Cytotoxic effects of zeolite-binase complexes toward colorectal cancer Caco2 cells were characterized after 24 and 48 h of incubation with cells using MTT-test. Zeolites were toxic by itselfs and reduced cells viability by 30% (clinoptilolite), 40% (chabazite), and 70% (natrolite) after 48 h of incubation. Binase complexes with clinoptilolite as we...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions Epidemiological studies have repeatedly helped identify definitive triggers for several diseases. As highlighted in this perspective report, previous studies strongly argue for the interplay between intrinsic factors and putative preventable extrinsic triggers/promoters for CTCL. Given the evidence of geographical regional clustering of CTCL patients, CTCL occurrence in unrelated family members and recent evidence implicating S. aureus in the pathogenesis/progression of CTCL, more research is needed to decipher the precise mechanism by which specific environmental exposures may be driving the pathogenesis of t...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center believes novel CAR T-cell therapy will be part of future, standard-of-care treatment for malignant pleural mesothelioma. The therapy involves the laboratory reprograming of a patient’s T cells — a type of white blood cell — to attack the cancer by targeting mesothelin, a surface protein. CAR T-cell therapy is a form of immunotherapy that could extend mesothelioma survival significantly. “That’s my goal. That’s what we’ve been working toward for many years,” Adusumilli told The Mesothelioma Center at Asbestos.com....
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
This study aimed to explore whether a correlation exists between the incidence and mortality of cancers and normalized internet search volumes on the big data platform, Baidu. We also assessed whether the distribution of people who searched for specific types of cancer differed by gender. Finally, we determined whether there were regional disparities among people who searched the Web for cancer-related information. Methods: Standard Boolean operators were used to choose search terms for each type of cancer. Spearman’s correlation analysis was used to explore correlations among monthly search index values for each can...
Source: Journal of Medical Internet Research - Category: General Medicine Authors: Source Type: research
The National Cancer Institute in Rockville, Maryland, has opened an innovative clinical trial for patients with peritoneal mesothelioma that will explore the safety and effectiveness of a novel CAR T-cell therapy. The phase I trial also is being conducted at Washington University in St. Louis. It is aimed at patients whose disease has relapsed after initial chemotherapy treatment. It involves a laboratory modification of a patient’s T cells — a type of white blood cell — that can help the immune system kill the cancer. CAR T-cell therapy is a form of gene therapy that has been highly successful with blood...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The National Cancer Institute awarded a five-year, $10.7 million grant to the Abramson Cancer Center at the University of Pennsylvania to develop CAR T-cell therapy for mesothelioma and lung cancer. The hopes are high for a breakthrough. The program involves a laboratory modification of a patient’s T cells — a type of white blood cell — that prompts the immune system to attack cancer cells. The therapy also is known as chimeric antigen receptor T-cell therapy. It already is revolutionizing the way some blood and bone marrow cancers are treated. The grant is designed to investigate whether this type of gen...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Ataxia-telangiectasia (A-T), an autosomal recessive disorder characterized by progressive neurologic dysfunction, oculocutaneous telangiectasia, immunodeficiency, and cancer susceptibility, is caused by mutations in the ATM gene. A previous study of 4 A-T patients identified 2 rare homozygous missense mutations residing on the same allele of the ATM gene: c.1514T>C and c.1547T>C, which were shown to decrease ATM levels and increase T-cell acute lymphoblastic leukemia predisposition. We studied 5 patients from 2 consanguineous Bedouin families of the same tribe, presenting with A-T. Whole-exome sequencing data identif...
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Original Articles Source Type: research
The University of Pennsylvania's Abramson Cancer Center had received a $10.7 million grant from the National Cancer Institute to study CAR-T cells in solid tumors The five-year grant from the NCI's will support new experimental approaches in lung cancer and mesothelioma being conducted by Penn researchers at its translational center of excellence for lung cancer immunology “Although CAR-T cells have been revolutionized the treatment of leukemia and bone marrow cancers, we have not yet had the…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Chemotherapy | Clinical Trials | Environmental Health | Grapes | Hospitals | Leukemia | Mesothelioma | Molecular Biology | Study | Toxicology